Here, we report the efficacy of such personalized combination treatment regimens which achieve efficacious mTOR blockade as well as tandem targeting of other tumor vulnerabilities to yield meaningful outcomes in treatment of advanced refractory cancers. This evidence concerns the gene MTOR and neoplasm.